<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527096</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 167 Lamidol</org_study_id>
    <secondary_id>2015-001492-44</secondary_id>
    <nct_id>NCT02527096</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)</brief_title>
  <official_title>A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir®) and Dolutegravir(Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective is to evaluate the antiviral efficacy of 48 weeks treatment with the
      two-drugs combination dolutegravir(Tivicay®) and lamivudine(TEpivir®) in HIV-1 infected
      patients virologically suppressed with triple HAART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives:

      The following parameters will be evaluated :

        -  Evolution of CD4 cells and CD8 cells

        -  Tolerance to treatment

        -  Emergence of resistance mutations at time of virological failure

        -  HIV viral load measured with ultrasensitive assay (threshold 1 copy/mL) at Day 0, Week
           8, Week 32 and Week 56

        -  Influence of total DNA at Day 0 on the occurrence of virological failure or blip

        -  Plasma levels of dolutegravir(Tivicay®) and lamivudine in participants with virological
           failure

        -  Adherence to treatment

        -  Quality of life

        -  Medico-economic aspects

        -  Dolutegravir(Tivicay®) and Nucleosidic Reverse Transcriptase Inhibitors (NRTIs) levels,
           and HIV viral load in semen in a subgroup of 20 participants.

      Methodology:

      Pilot trial, multicentric, national, prospective, no randomized and no comparative.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological success without any intercurrent event leading to interrupt the strategy of the trial (analysis)</measure>
    <time_frame>from week 8 to week 56 (± 4 weeks)</time_frame>
    <description>Virological failure is defined by plasma HIV RNA &gt; 50 cp/mL on 2 following samples at 2 to 4 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of CD4 and CD8 lymphocytes count (analysis)</measure>
    <time_frame>from week 8 to week 32 and week 56</time_frame>
    <description>Evaluation was calculated as the CD4 count at the corresponding week minus the baseline CD4 count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who discontinued the strategy of the trial for toxicity or with adverse event of grade 3 or 4 (analysis)</measure>
    <time_frame>week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of resistance mutations in plasma in case of virological failure</measure>
    <time_frame>week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with plasma HIV RNA &lt; 1 cp/mL</measure>
    <time_frame>Day 0, week 8, week 32 and week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of total DNA on the occurrence of virological failure or blip</measure>
    <time_frame>from Day 0 to week 56</time_frame>
    <description>Influence of total DNA at Day 0 on the occurrence of virological failure or blip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of concentrations of dolutegravir(Tivicay®) and lamivudine(Epivir®) in case of virological failure or with a blip</measure>
    <time_frame>week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of adherence to treatment (self-reported)</measure>
    <time_frame>Day 0, week 4, week 8, week 32 and week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of quality of life (self-reported)</measure>
    <time_frame>Day 0, week 8 and week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Medico-economic substudy (analysis)</measure>
    <time_frame>week 56</time_frame>
    <description>Evaluation of medico-economic aspects. Evaluate the direct medical cost related to dolutegravir and lamivudine versus the cost of the previous treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm substudy measure of concentration</measure>
    <time_frame>Week 8 and week 32</time_frame>
    <description>Measure of concentrations of dolutegravir and NRTI, and HIV RNA in semen at Week 8 and Week 32 in a subgroup of 20 participants</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>dolutegravir(Tivicay®) and lamivudine(Epivir®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir (Tivicay®) - Phase 1</intervention_name>
    <description>• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.</description>
    <arm_group_label>dolutegravir(Tivicay®) and lamivudine(Epivir®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine (Epivir®) - Phase 2</intervention_name>
    <description>• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.</description>
    <arm_group_label>dolutegravir(Tivicay®) and lamivudine(Epivir®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir (Tivicay®) - Phase 2</intervention_name>
    <description>• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.</description>
    <arm_group_label>dolutegravir(Tivicay®) and lamivudine(Epivir®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected patient

          -  Age ≥ 18 years

          -  CD4 cell count nadir &gt; 200/mm3

          -  Genotype on pre-HAART interpreted with the last version of the ANRS AC11 resistance
             group's algorithm which presents:

               -  no major mutation on protease among: D30N, V32I, M46I/L, I47A/V, G48V, I50L/V,
                  154M/L, L76V, V82A/F/T/S, I84V, N88D/S, L90M,- no mutation on RT (except the
                  mutation A98S if the patient is not infected by the virus subtype C),

               -  no mutation on integrase (if the genotype is available),

          -  First-line treatment with suppressive triple HAART (2 NRTI + either 1 PI/r, 1 NNRTI or
             1 INI). The initial treatment may have changed a maximum of two times but only once
             for toxicity (changes such Epivir / Ziagen to Kivexa, are not considered as a change
             of treatment). However, treatment has to be unchanged in the last 6 months

          -  Plasma HIV RNA ≤ 50 copies/mL for ≥ 2 years with at least 2 viral load determinations
             per year. Blips (HIV viral load between 50 and 200 copies/mL but ≤ 50 copies/mL on
             control sample) are allowed except in the last 6 months. The total number of blips
             must not exceed 3 in the last 2 years

          -  Negative Hepatitis Bs Antigen

          -  Effective contraception for women of childbearing potential

          -  Informed consent form signed by patient and investigator

          -  Patient enrolled in or a beneficiary of a Social Security programme (State Medical Aid
             (&quot;Aide Médicale d'Etat&quot; AME in France) is not a Social Security programme)

        Exclusion Criteria:

          -  HIV-2 infection

          -  Positive HBc Ac isolated

          -  Hepatitis B Virus (HBV) co-infected patients (positive Hepatitis Bs Ag at inclusion)

          -  Chronic hepatitis C currently treated or needing therapy in the next 12 months

          -  History of HIV-associated neurocognitive disorders

          -  Current pregnancy or breastfeeding

          -  No effective contraception for the women of childbearing

          -  Previous treatment with chemotherapy (except bleomycin on Kaposi disease's treatment)
             or immunotherapy

          -  Grade &gt; 2 abnormality for usual biological parameters (liver function tests, blood
             cell count)

          -  ALT(Alanine Aminotransferase) ≥ 5 x upper limit of normal value (ULN) or AST
             (Aspartate Aminotransferase) ≥ 3 x ULN and bilirubinemia ≥ 1.5 x ULN (with 35% direct
             bilirubinemia)

          -  Unstable liver disease (ascitis, encephalopathy, coagulopathy, hypoalbuminemia,
             oesophageal or gastric varices or persistent jaundice)

          -  Known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic
             gallstones)

          -  Creatininemia clearance below 50 mL/min (Cockroft-Gault method)

          -  History or presence of allergy to the trial drugs or their components

          -  Severe hepatic insufficiency (Child Pugh Class C)

          -  Patients participating in another clinical trial including an exclusion period that is
             still in force during the screening phase

          -  Patients under &quot;sauvegarde de justice&quot; (judicial protection due to temporarily and
             slightly diminished mental or physical faculties) or under legal guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique JOLY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies Infectieuses, Hôpital Bichat-Claude Bernard, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yazdan YAZDANPANAH, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Service des Maladies Infectieuses, Hôpital Bichat-Claude Bernard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland LANDMAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Médecine et Epidémiologie Appliquée (IMEA), Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Zobda-Quitman</name>
      <address>
        <city>Fort de France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpial Bicêtre</name>
      <address>
        <city>Le Kremelin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chaudiac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Pernignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gustave Dron</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr/</url>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dolutegravir(Tivicay®)</keyword>
  <keyword>lamivudine(Epivir®)</keyword>
  <keyword>HIV-1</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

